/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Marker Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.28 0.0672(6.72%) MRKR at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 1.2
Highest Today 1.2899
Today’s Open 1.2
Prev. Close 1.19
52 Week High 5.95
52 Week Low 0.81
Day’s Range: Low 1.2 High 1.2899
52-Week Range: Low 0.81 High 5.95
1 day return -
1 Week return +2.43
1 month return +41.36
3 month return +44.13
6 month return -16.55
1 year return -63.79
3 year return -58.0
5 year return -92.63
10 year return -

Institutional Holdings

NEA Management Company, LLC 12.56

Blue Owl Capital Holdings LP 4.28

Aisling Capital Management LP 2.51

Vanguard Group Inc 2.13

Alyeska Investment Group, L.P. 1.65

Vanguard Total Stock Mkt Idx Inv 1.40

Geode Capital Management, LLC 0.74

Vanguard Institutional Extnd Mkt Idx Tr 0.68

LPL Financial Corp 0.57

Renaissance Technologies Corp 0.54

Fidelity Extended Market Index 0.37

Vifag 2002 SICAV 0.23

Invst LLC 0.18

Jane Street Group LLC 0.17

State Street Corp 0.16

Advisor Group Holdings, Inc. 0.15

Creative Planning Inc 0.13

Dimensional Fund Advisors, Inc. 0.12

Matrix Asset Advisors Inc 0.12

Fidelity Series Total Market Index 0.11

Fidelity Total Market Index 0.10

Spartan Extended Market Index Pool F 0.10

Susquehanna International Group, LLP 0.10

Northern Trust Corp 0.08

NT Ext Equity Mkt Idx Fd - NL 0.04

Fidelity Nasdaq Composite Index 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Tower Research Capital LLC 0.03

Vanguard U.S. Eq Idx £ Acc 0.02

State St US Extended Mkt Indx NL Cl C 0.02

SBI Securities Co Ltd 0.01

UBS Group AG 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

BNYM Mellon SL Market Completion UC1 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

SSgA U.S. Total Market Index Strategy 0.01

Northern Trust Wilshire 5000 0.00

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15.40 M

PB Ratio 1.0822

PE Ratio 0.0

Enterprise Value 2.31 M

Total Assets 22.02 M

Volume 186208

Company Financials

Annual Revenue FY23:9013544 9.0M, FY22:9004530 9.0M, FY21:1241710 1.2M, FY20:466785 0.5M, FY19:213194 0.2M

Annual Profit FY23:null 0.0M, FY22:9004530 9.0M, FY21:1241710 1.2M, FY20:466785 0.5M, FY19:213194 0.2M

Annual Net worth FY23:-9290163 -9.3M, FY22:-29915605 -29.9M, FY21:-41873171 -41.9M, FY20:-28526328 -28.5M, FY19:-20327122 -20.3M

Quarterly Revenue Q3/2025:1232938 1.2M, Q2/2025:861184 0.9M, Q1/2025:349104 0.3M, Q3/2024:1926020 1.9M, Q2/2024:1169236 1.2M

Quarterly Profit Q3/2025:1232938 1.2M, Q2/2025:-3315870 -3.3M, Q1/2025:-2786323 -2.8M, Q3/2024:1926020 1.9M, Q2/2024:1169236 1.2M

Quarterly Net worth Q3/2025:-1998662 -2.0M, Q2/2025:-4015564 -4.0M, Q1/2025:-4446184 -4.4M, Q3/2024:-2308192 -2.3M, Q2/2024:-2192677 -2.2M

Fund house & investment objective

Company Information Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Dr. Juan F. Vera M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow